Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:34:11.740Z.
Calculation as of: 2026-10-06T17:34:11.740Z.
Quote observation: 2026-10-06T17:30:13.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 680db3c2305e98602fe5277f15244516f30a0ab53cbf5830e5b41f5092839f7c
PE RATIO
N/A
Market Cap
$859.24M
PE Ratio
2.85
TTM Avg
3.74
3Y Avg
21.90
5Y Avg
21.90
Market Cap
$860.24M
PE Ratio
N/A
TTM Avg
43.56
3Y Avg
43.56
5Y Avg
43.56
Market Cap
$833.66M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$832.81M
PE Ratio
N/A
TTM Avg
76.88
3Y Avg
76.88
5Y Avg
76.88
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SL Science Holding Ltd (SLBT) | $864.30M | N/A | N/A | N/A | N/A |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $859.24M | 2.85 | 3.74 | 21.90 | 21.90 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $860.24M | N/A | 43.56 | 43.56 | 43.56 |
| SI-BONE, Inc. (SIBN)vs › | $860.05M | N/A | N/A | N/A | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $845.91M | N/A | 151.06 | 53.96 | 49.56 |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $833.66M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $880.50M | 5.71 | 5.80 | 5.80 | 5.80 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $832.81M | N/A | 76.88 | 76.88 | 76.88 |
| Beta Bionics, Inc. (BBNX)vs › | $830.51M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $830.36M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
